Open AccessThe role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Author(s) -
Camillo Porta,
Federica Tagliani
Publication year - 2011
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2008.111
Subject(s) - medicine , chronic myelogenous leukemia , imatinib , lyn , imatinib mesylate , nilotinib , tyrosine kinase , pharmacology , tyrosine kinase inhibitor , tolerability , leukemia , abl , cancer research , receptor , myeloid leukemia , adverse effect , cancer
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...